Actively Recruiting

Phase 4
Age: 45Years - 79Years
All Genders
ID03264352

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes to Reduce Cardiovascular Events

Led by XueQing Yu · Updated on 2025-03-12

11414

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating how lowering blood pressure affects adults with type 2 diabetes who have high-normal blood pressure. This large, randomized, open-label study involves over 11,000 participants aged 45 to 79 years with sitting systolic blood pressure between 120 and 139 mm Hg and diastolic below 90 mm Hg. The trial aims to see if intensive blood pressure control reduces major cardiovascular and cerebrovascular events by 20% compared to standard treatment. Participants are randomly assigned to one of two groups. The intensive group receives antihypertensive medications including Allisartan Isoproxil 240 mg daily and Amlodipine 5 to 10 mg daily to lower systolic pressure below 120 mm Hg. The standard group receives no medication until blood pressure reaches 140/90 mm Hg or higher, then treatment follows current guidelines to reduce it below those levels. The study will follow participants for a median of four years. Throughout the study, researchers will monitor cardiovascular events such as stroke, heart attack, hospitalizations for heart failure or unstable angina, and death. They will also assess kidney function, diabetic retinopathy, peripheral arterial disease, new atrial fibrillation, cancer, and quality of life. Blood pressure will be regularly measured to ensure targets are met. Safety and outcomes will be analyzed up to 60 months after randomization, with interim analyses planned during the study.

CONDITIONS

Brief Title

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes

Who Can Participate

Age: 45Years - 79Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Any sex
  • Age between 45 and 79 years
  • Seated blood pressure 120-139 mm Hg systolic and below 90 mm Hg diastolic
  • Diagnosed with type 2 diabetes mellitus and currently on diabetic therapy
  • Provided informed consent and able to participate in long-term follow-up
Not Eligible

You will not qualify if you...

  • Poor blood glucose control with HbA1c above 10.0%
  • Use of antihypertensive medications within the past month
  • History of hypoglycemic coma or seizure
  • Diagnosis of type 1 diabetes mellitus
  • Liver enzymes (ALT or AST) more than three times the upper normal limit
  • Estimated glomerular filtration rate below 45 ml/min/1.73m2
  • History of congestive heart failure with ejection fraction below 40%
  • Coronary artery disease needing RAS blockers for secondary prevention
  • Stroke within 6 months before enrollment
  • Urinary albumin to creatinine ratio 300 mg/g or higher
  • Known contraindications to study medications
  • History of psychological or mental disorder
  • Pregnancy, planning pregnancy, or breastfeeding
  • Severe diseases including severe heart diseases
  • Expected life expectancy less than 3 years
  • Malignancy deemed unsuitable by investigators
  • Currently participating in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 60 months

Participants receive either intensive antihypertensive medication to reduce systolic blood pressure below 120 mm Hg or standard treatment to maintain systolic blood pressure below 140 mm Hg, with medications adjusted as needed.

Regular visits for medication management and monitoring during treatment

Follow-up

Duration - Up to 60 months

Participants are monitored for major cardiovascular events and other health outcomes after treatment initiation.

Periodic visits for health assessments and event monitoring

Trial Site Locations

Total: 1 location

1

Guangdong General Hospital

Guangzhou, Guangdong, China, 501080

Actively Recruiting

Loading map...

Research Team

J

Jiyan Chen, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

24-hour Movement Behaviors Among Adults with Type 2 Diabetes...

Diabetes Mellitus, Type 2

Actively Recruiting

1 location

A Multiple Dose Clinical Study to Evaluate the Safety, Toler...

Diabetes Mellitus, Type 2

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here